Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Products
Our Programs
Patients and Physicians
Inside Seres
Open Positions
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Dec 16, 2024

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Dec 09, 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Nov 22, 2024

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 13, 2024

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 06, 2024

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Sep 30, 2024

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 26, 2024

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 13, 2024

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 12, 2024

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Aug 13, 2024

Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2024 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook